ArticleEuropean journal of haematology2022

Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis.

Ivan Spicka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.